2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level

BACKGROUND: Respiratory syncytial virus (RSV) can cause serious lower respiratory tract disease (LRTD) among older adults. There is no licensed RSV vaccine. In CYPRESS (a randomized, double-blind, placebo-controlled, phase 2b proof-of concept trial; NCT03982199), an Ad26.RSV.preF/RSV preF protein va...

Descripción completa

Detalles Bibliográficos
Autores principales: Comeaux, Christy A, Falsey, Ann R, Williams, Kristi, Bart, Stephan, Ervin, John E, Bastian, Arangassery R, Menten, Joris, De Paepe, Els, Vandenberghe, Sjouke, Chan, Eric K H, Sadoff, Jerald, Douoguih, Macaya, Callendret, Benoit, Heijnen, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751781/
http://dx.doi.org/10.1093/ofid/ofac492.152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751781/
http://dx.doi.org/10.1093/ofid/ofac492.152

Ejemplares similares